Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. ADVM-022 is a single, in-office intravitreal injection gene therapy. ADVM-022 is being developed for the treatment of patients with chronic retinal diseases who respond to anti-vascular endothelial growth factor therapy, including wet age-related macular degeneration and diabetic macular edema. ADVM-022 utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. We show 31 historical shares outstanding datapoints in our ADVM shares outstanding history coverage, used to compute ADVM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADVM market cap history over the course of time is important for investors
interested in comparing ADVM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADVM versus a peer is one thing; comparing
ADVM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADVM can fluctuate over the course of history.
With this page we aim to empower investors researching ADVM by allowing them to research the ADVM market cap history. |
Free ADVM Email Alerts:
Video: The Importance of Market Cap
